Oxurion company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

oxurion.com

Stage

Unattributed | Alive

Total Raised

$35M

Last Raised

$35M | 1 yr ago

Revenue

$0000 

Mosaic Score

+30 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Oxurion

Oxurion is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in-house expertise and collaborations with academic institutions to build a strong pipeline of promising drug candidates in cardiovascular diseases, visual disorders, and cancer.

Oxurion Headquarter Location

Gaston Geenslaan 1

Leuven, B-3001,

Belgium

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Oxurion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxurion is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,750 items

Oxurion Patents

Oxurion has filed 24 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • G protein coupled receptors
  • Ophthalmology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/19/2019

7/7/2020

Clusters of differentiation, Diseases of the eye and adnexa, G protein coupled receptors, Transcription factors, Integrins

Grant

Application Date

8/19/2019

Grant Date

7/7/2020

Title

Related Topics

Clusters of differentiation, Diseases of the eye and adnexa, G protein coupled receptors, Transcription factors, Integrins

Status

Grant

Latest Oxurion News

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Jul 29, 2022

About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com. Important information about forward-looking statements Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws. For further information please contact: Oxurion NV

Oxurion Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxurion Rank

  • Where is Oxurion's headquarters?

    Oxurion's headquarters is located at Gaston Geenslaan 1, Leuven.

  • What is Oxurion's latest funding round?

    Oxurion's latest funding round is Unattributed.

  • How much did Oxurion raise?

    Oxurion raised a total of $35M.

  • Who are the investors of Oxurion?

    Investors of Oxurion include Negma Group and Gimv.

  • Who are Oxurion's competitors?

    Competitors of Oxurion include Oligomerix, Sierra Oncology, Dare Bioscience, Aphios, Array Biopharma and 13 more.

You May Also Like

A
AM-Pharma

AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.

Oligomerix Logo
Oligomerix

Oligomerix is a clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are potentially easy to administer and cost-effective. Its portfolio of compounds is expected to provide a lower-cost treatment alternative and/or complement to the emerging, high-cost therapeutic options, such as the monoclonal antibody products. Oligomerix was founded in 2006 and is based in West Harrison, New York.

B
BrainCells

BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

Cerecin Logo
Cerecin

Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

T
TargAnox

TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.